We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Clavis Pharma Licenses LVT Compound CP-4033 to Translational Therapeutics for Development in Aggressive Thyroid Tumours

News   Jun 06, 2011

 
Clavis Pharma Licenses LVT Compound CP-4033 to Translational Therapeutics for Development in Aggressive Thyroid Tumours
 
 
 

RELATED ARTICLES

Whole Genome Sequencing for Personalized Antibiotic Therapy

News

Researchers have added to evidence that rapid resistance gene sequencing technology can accurately speed the identification of specific antibiotic-resistant bacteria strains that sicken and kill some patients.

READ MORE

Specific Obesity-related Risk Factors for Kidney Cancer

News

A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors.

READ MORE

World’s First Genetically Enhanced Human Vascular Cells

News

Scientists have generated the world's first genetically enhanced human vascular cells by targeting a single longevity gene, FOXO3.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE